A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease.


Journal

Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897

Informations de publication

Date de publication:
03 Jul 2019
Historique:
received: 14 02 2019
accepted: 07 06 2019
entrez: 5 7 2019
pubmed: 5 7 2019
medline: 14 1 2020
Statut: epublish

Résumé

Kawasaki disease (KD) is a systemic vasculitis which may be associated with coronary artery aneurysms. A notable risk factor for the development of coronary artery aneurysms is resistance to intravenous immunoglobulin (IVIG) therapy, which comprises standard treatment for the acute phase of KD. The cause of IVIG resistance in KD is largely unknown; however, the contribution of genetic factors, especially variants in immune-related genes, has been suspected. To explore genetic variants related to IVIG-unresponsiveness, we designated KD patients who did not respond to both first and second courses of IVIG therapy as IVIG-unresponsive patients. Using genomic DNA from 30 IVIG-unresponsive KD patients, we performed pooled genome sequencing targeting 39 immune-related cytokine receptor genes. The single nucleotide variant (SNV), rs563535954 (located in the IL4R locus), was concentrated in IVIG-unresponsive KD patients. Individual genotyping showed that the minor allele of rs563535954 was present in 4/33 patients with IVIG-unresponsive KD, compared with 20/1063 individuals in the Japanese genome variation database (odds ratio = 7.19, 95% confidence interval 2.43-21.47). Furthermore, the minor allele of rs563535954 was absent in 42 KD patients who responded to IVIG treatment (P = 0.0337), indicating that a low-frequency variant, rs563535954, is associated with IVIG-unresponsiveness in KD patients. Although rs563535954 is located in the 3'-untranslated region of IL4R, there was no alternation in IL4R expression associated with the mior allele of rs563535954. However, IVIG-unresponsive patients that exhibited the minor allele of rs563535954 tended to be classified into the low-risk group (based on previously reported risk scores) for prediction of IVIG-resistance. Therefore, IVIG-unresponsiveness associated with the minor allele of rs563535954 might differ from IVIG-unresponsiveness associated with previous risk factors used to evaluate IVIG-unresponsiveness in KD. These findings suggest that the SNV rs563535954 could serve as a predictive indicator of IVIG-unresponsiveness, thereby improving the sensitivity of risk scoring systems, and may aid in prevention of coronary artery lesions in KD patients.

Sections du résumé

BACKGROUND BACKGROUND
Kawasaki disease (KD) is a systemic vasculitis which may be associated with coronary artery aneurysms. A notable risk factor for the development of coronary artery aneurysms is resistance to intravenous immunoglobulin (IVIG) therapy, which comprises standard treatment for the acute phase of KD. The cause of IVIG resistance in KD is largely unknown; however, the contribution of genetic factors, especially variants in immune-related genes, has been suspected.
METHODS METHODS
To explore genetic variants related to IVIG-unresponsiveness, we designated KD patients who did not respond to both first and second courses of IVIG therapy as IVIG-unresponsive patients. Using genomic DNA from 30 IVIG-unresponsive KD patients, we performed pooled genome sequencing targeting 39 immune-related cytokine receptor genes.
RESULTS RESULTS
The single nucleotide variant (SNV), rs563535954 (located in the IL4R locus), was concentrated in IVIG-unresponsive KD patients. Individual genotyping showed that the minor allele of rs563535954 was present in 4/33 patients with IVIG-unresponsive KD, compared with 20/1063 individuals in the Japanese genome variation database (odds ratio = 7.19, 95% confidence interval 2.43-21.47). Furthermore, the minor allele of rs563535954 was absent in 42 KD patients who responded to IVIG treatment (P = 0.0337), indicating that a low-frequency variant, rs563535954, is associated with IVIG-unresponsiveness in KD patients. Although rs563535954 is located in the 3'-untranslated region of IL4R, there was no alternation in IL4R expression associated with the mior allele of rs563535954. However, IVIG-unresponsive patients that exhibited the minor allele of rs563535954 tended to be classified into the low-risk group (based on previously reported risk scores) for prediction of IVIG-resistance. Therefore, IVIG-unresponsiveness associated with the minor allele of rs563535954 might differ from IVIG-unresponsiveness associated with previous risk factors used to evaluate IVIG-unresponsiveness in KD.
CONCLUSION CONCLUSIONS
These findings suggest that the SNV rs563535954 could serve as a predictive indicator of IVIG-unresponsiveness, thereby improving the sensitivity of risk scoring systems, and may aid in prevention of coronary artery lesions in KD patients.

Identifiants

pubmed: 31269967
doi: 10.1186/s12969-019-0337-2
pii: 10.1186/s12969-019-0337-2
pmc: PMC6610867
doi:

Substances chimiques

IL4R protein, human 0
Immunoglobulins, Intravenous 0
Interleukin-4 Receptor alpha Subunit 0
RNA, Messenger 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34

Subventions

Organisme : KAKENHI grant
ID : 16K10020
Organisme : KAKENHI grant
ID : 18K15666

Références

Pediatrics. 2000 Jun;105(6):E78
pubmed: 10835091
Nat Genet. 2000 Aug;25(4):375-6
pubmed: 10932175
Pediatr Int. 2001 Jun;43(3):211-7
pubmed: 11380911
Clin Exp Allergy. 2004 Mar;34(3):445-9
pubmed: 15005739
Clin Exp Immunol. 2004 Aug;137(2):444-9
pubmed: 15270865
Pediatr Int. 2005 Apr;47(2):232-4
pubmed: 15771703
Circulation. 2006 Jun 6;113(22):2606-12
pubmed: 16735679
Respir Med. 2007 Jan;101(1):186-90
pubmed: 16757160
J Pediatr. 2006 Aug;149(2):237-40
pubmed: 16887442
Eur J Pediatr. 2007 Feb;166(2):131-7
pubmed: 16896641
N Engl J Med. 1991 Jun 6;324(23):1633-9
pubmed: 1709446
Nat Genet. 2008 Jan;40(1):35-42
pubmed: 18084290
Pediatr Infect Dis J. 2008 Feb;27(2):155-60
pubmed: 18174868
J Immunol. 2009 Aug 1;183(3):1607-16
pubmed: 19592641
Pediatr Infect Dis J. 2010 Jun;29(6):483-8
pubmed: 20104198
Hum Mol Genet. 2010 Jul 15;19(14):2898-906
pubmed: 20423928
Hawaii Med J. 2010 Aug;69(8):194-7
pubmed: 20845285
Biomol Ther (Seoul). 2010 Apr;18(2):135-144
pubmed: 21072258
Nature. 2011 Jun 19;475(7354):110-3
pubmed: 21685887
Nat Genet. 2011 Nov 13;43(12):1241-6
pubmed: 22081228
Nat Genet. 2012 Mar 25;44(5):522-5
pubmed: 22446961
Nat Genet. 2012 Mar 25;44(5):517-21
pubmed: 22446962
J Epidemiol. 2012;22(3):216-21
pubmed: 22447211
Arthritis Rheum. 2013 Mar;65(3):805-14
pubmed: 23440694
J Pediatr. 2013 Sep;163(3):811-5
pubmed: 23647775
N Engl J Med. 1986 Aug 7;315(6):341-7
pubmed: 2426590
PLoS One. 2014 Mar 12;9(3):e91118
pubmed: 24621571
PLoS One. 2014 Aug 22;9(8):e105236
pubmed: 25148534
Vascul Pharmacol. 2015 Oct;73:57-63
pubmed: 26231284
Nat Commun. 2015 Aug 21;6:8018
pubmed: 26292667
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
PLoS One. 2016 May 23;11(5):e0156002
pubmed: 27214384
Pediatr Int. 2017 Apr;59(4):397-403
pubmed: 27743415
Korean J Pediatr. 2016 Oct;59(10):408-413
pubmed: 27826327
Pediatr Infect Dis J. 1988 Dec;7(12):863-6
pubmed: 3211629
Pediatr Cardiol. 1986;7(1):3-9
pubmed: 3774580
Arerugi. 1967 Mar;16(3):178-222
pubmed: 6062087
Lancet. 1984 Nov 10;2(8411):1055-8
pubmed: 6209513
Circulation. 1996 Sep 15;94(6):1379-85
pubmed: 8822996
Eur J Pediatr. 1997 Jan;156(1):30-2
pubmed: 9007486
Int Arch Allergy Immunol. 1997 Feb;112(2):152-6
pubmed: 9030095
N Engl J Med. 1997 Dec 11;337(24):1720-5
pubmed: 9392697
Pediatr Infect Dis J. 1998 Dec;17(12):1144-8
pubmed: 9877364

Auteurs

Yuji Amano (Y)

Department of Microbiology and Immunology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Yohei Akazawa (Y)

Department of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Jun Yasuda (J)

Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Kazuhisa Yoshino (K)

Department of Microbiology and Immunology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Katsuhiko Kojima (K)

Department of Microbiology and Immunology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Norimoto Kobayashi (N)

Department of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Satoshi Matsuzaki (S)

Department of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Masao Nagasaki (M)

Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Graduate School of Information Science, Tohoku University, 6-3-09, Aramaki Aza-Aoba, Aoba-ku, Sendai, Miyagi, 980-8579, Japan.

Yosuke Kawai (Y)

Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Naoko Minegishi (N)

Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Noriko Ishida (N)

Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Noriko Motoki (N)

Department of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Akira Hachiya (A)

Department of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Yozo Nakazawa (Y)

Department of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.

Masayuki Yamamoto (M)

Tohoku Medical Megabank Organization, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.
Graduate School of Medicine, Tohoku University, 2-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.

Kenichi Koike (K)

Department of Pediatrics, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan.
Shinonoi General Hospital, Minami Nagano Center, 666-1 Shinonoi, Nagano City, Nagano, 388-8004, Japan.

Toshikazu Takeshita (T)

Department of Microbiology and Immunology, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, 390-8621, Japan. takesit@shinshu-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH